Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis

Exclusion Criteria

• •Female subjects who are pregnant, nursing or planning a pregnancy during the study.
• •Subjects with known hypersensitivity to any components of the test medication.
• •Subjects with non-plaque psoriasis (e.g. guttate, erythrodermic) or other related diseases not classified as plaque psoriasis.
• •Subjects whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas.
• •Subjects requiring any other medication (topical or systemic) that may affect the course of the disease during the study period as determined by the study investigators.
• •Subjects using biologics or any other systemic treatment (e.g. immunosuppressants, acitretin) for psoriasis within 12 weeks of entering the study.
• •Subjects using systemic corticosteroids within 28 days of entering the study
• •Subjects using topical corticosteroids or other topical therapies (other than emollients) at the treatment area locations within 14 days of entering the study
• •Subjects using phototherapy (UVB, PUVA) on target treatment sites within 4 weeks of entering the study.
• •Subjects with overt pre-existing telangiectasias or skin atrophy at intended treatment sites (treatment areas).
• •Subjects who are using any medication or has any disease which in the judgment of the investigator will interfere with the conduct or interpretation of the study.